Treatment with TGF-β1 (Chen et al., 2015) or IFN-β (Mudò et al., 2019) are protective in rat models of AD and are thought to work by decreasing proinflammatory IL-1β, TNF-α, and iNOS, and by promoting anti-inflammatory IL-10. Here, TNF is linked to Alzheimer disease.